Pharmacokinetic characteristics of ritonavir, zidovudine, lamivudine, and stavudine in children with human immunodeficiency virus infection.
about
Population pharmacokinetics of lamivudine in human immunodeficiency virus-exposed and -infected infantsPopulation pharmacokinetics study of recommended zidovudine doses in HIV-1-infected childrenPharmacokinetic optimization of antiretroviral therapy in children and adolescents.Assessing the interest to participate in a dengue vaccine efficacy trial among residents of Puerto Rico.
P2860
Pharmacokinetic characteristics of ritonavir, zidovudine, lamivudine, and stavudine in children with human immunodeficiency virus infection.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Pharmacokinetic characteristic ...... unodeficiency virus infection.
@en
Pharmacokinetic characteristic ...... unodeficiency virus infection.
@nl
type
label
Pharmacokinetic characteristic ...... unodeficiency virus infection.
@en
Pharmacokinetic characteristic ...... unodeficiency virus infection.
@nl
prefLabel
Pharmacokinetic characteristic ...... unodeficiency virus infection.
@en
Pharmacokinetic characteristic ...... unodeficiency virus infection.
@nl
P2093
P2860
P1433
P1476
Pharmacokinetic characteristic ...... unodeficiency virus infection.
@en
P2093
Andrew Wiznia
Courtney V Fletcher
Kenneth McIntosh
Kenneth Stanley
Sharon A Nachman
P2860
P304
P356
10.1592/PHCO.24.5.453.33343
P407
P577
2004-04-01T00:00:00Z